Compare AbbVie Inc (ABBV) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Goldman Sachs Group Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Goldman Sachs Group Inc trades at $1,029.75 (market cap $307.69B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GS | |
|---|---|---|
Market Cap | $449.91B | $307.69B |
Sector | Health | Financials |
52-Week High | $261.07 | $1.11K |
52-Week Low | $184.85 | $696.57 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 1.73% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Goldman Sachs (GS) trades at $1,055.29, up 3.36% with a bullish technical outlook and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue grew to $58.28B in 2025, and net income margin improved to 29.89%. The company is positioned to benefit from a surge in IPO activity, including leading high-profile deals like Anthropic's upcoming offering.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Key risks include volatile cash flows and high leverage, but robust investment banking pipelines and CEO optimism about market 'greed mode' support growth. Analyst sentiment is mixed but leans positive, with 40% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
